Menu
GWAS Study

Genome-wide association analysis reveals 12q13.3-q14.1 as new risk locus for sarcoidosis.

Hofmann S, Fischer A, Nothnagel M et al.

22936702 PubMed ID
GWAS Study Type
9275 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

HS
Hofmann S
FA
Fischer A
NM
Nothnagel M
JG
Jacobs G
SB
Schmid B
WM
Wittig M
FA
Franke A
GK
Gaede KI
SM
Schürmann M
PM
Petrek M
MF
Mrazek F
PS
Pabst S
GC
Grohé C
GJ
Grunewald J
RM
Ronninger M
EA
Eklund A
RP
Rosenstiel P
HK
Höhne K
ZG
Zissel G
MJ
Müller-Quernheim J
SS
Schreiber S
Chapter II

Abstract

Summary of the research findings

Sarcoidosis is a systemic inflammatory disease of unknown aetiology, influenced by genetic and environmental factors. However, the loci so far identified for sarcoidosis explain only a part of its assumed heritability. To identify further susceptibility loci, we performed a genome-wide association analysis using the Affymetrix 6.0 Human GeneChip followed by validation and replication stages. After quality control, 637 cases, 1233 controls and 677 619 single-nucleotide polymorphisms (SNPs) were available for an initial screening. 99 SNPs were selected for validation in an independent study panel (1664 patients, 2932 controls). SNP rs1050045 was significantly associated with sarcoidosis (corrected p=0.0215) in the validation panel and yielded a p-value of 9.22 × 10(-8) (OR 1.24) in the meta-analysis of the screening and validation stage. A meta-analysis of three populations from Germany, the Czech Republic and Sweden confirmed this finding (p = 0.024; OR 1.14). Fine-mapping and mRNA expression studies pointed to osteosarcoma amplified 9 (OS9) as the most likely candidate for the underlying risk factor. The OS9 protein plays an important role in endoplasmic reticulum-associated protein degradation and acts during Toll-like receptor induced activation of myeloid cells. Expression analyses of OS9 mRNA provide evidence for a functional mechanism underlying the detected association signal.

637 European ancestry cases, 1,233 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

9275
Total Participants
GWAS
Study Type
Yes
Replicated
3,121 European ancestry cases, 4,284 European ancestry controls
Replication Participants
European
Ancestry
Sweden, Czech Republic, Germany
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.